Illumina Ventures, established in 2016 and based in Foster City, California, is an independently managed venture capital fund in a strategic partnership with Illumina, the world's leading genomics solutions provider. The fund primarily invests in early-stage companies within the life science and healthcare sectors, both in the United States and internationally. Illumina Ventures leverages its strategic partnership to provide capital and access to Illumina's expertise and vision, adding value to investments in genomics applications across life science research, healthcare, agriculture, environmental science, and personal wellness. The fund typically co-invests with other leading institutional and strategic investors.
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.
Attovia Therapeutics
Series B in 2024
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.
Attovia Therapeutics
Series A in 2023
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.